INTRODUCTION
Testicular cancer is a rare disease. A total of 78 cases have been diagnosed in 2010, with an age standardized rate of 0.8 cases/100,000 representing 1.7% of all diagnosed cancer in Saudi males (www.scr.org.sa). Owing to the rarity of the This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of patients diagnosed with testicular germ cell tumors. It is categorized according to the stage of the disease using the tumor-node-metastasis staging system 7 th edition. The guidelines are presented with supporting evidence level, they are based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi Oncology Society and Saudi Urological Association. Considerations to the local availability of drugs, technology and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and health care policy makers in the management of patients diagnosed with testicular germ cell tumors.
disease and the multidisciplinary approach in managing testis cancer, the group recommended that all testicular cancer cases should be managed in tertiary care centers.
Staging
• The American Joint Committee on Cancer tumor-node-metastasis staging for testis cancer (7 th edition 2010) was used. [1] 2. Evaluation of testicular tumors 2.1. Ultrasound of the scrotum is recommended to diagnose the tumor 2.2. S e r u m t u m o r m a r ke r s i n c l u d e s a l p h a fetoprotein (AFP), beta human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase should prior to orchiectomy 2.3. Computed tomography (CT) chest, abdomen, and pelvis should performed for confirmed testicular cancer.
Risk stratification
• The International Germ Cell Cancer Collaborative Group risk classification.
Treatment of testicular germ cell cancer
General considerations:
• Patients at all stages should undergo urgent inguinal orchiectomy unless the clinical situation requires immediate chemotherapy in patients with a testicular mass and clear germ cell malignancy based on elevated tumor markers • Trans-scrotal biopsy or orchiectomy for any intra-testicular lesion is absolutely contra-indicated • All patients who will undergo treatment with chemotherapy, retroperitoneal lymph node dissection (RPLND), or radiotherapy should be offered sperm banking. To maintain treatment intensity, chemotherapy cycles should be repeated every 3 weeks, independent of leukocyte count • Tumor markers are to be determined immediately before the start of each new chemotherapy cycle. The treatment will depend on the histological subtype as follow: 4.1. Seminoma Further treatment will depend on the stage: 4.1.1. Stage I 4.1.1.1. Surveillance: Is considered the preferred strategy, except in patients with expected poor compliance or with primary tumor size ≥4 cm and ≥pT2 (evidence level [EL-1]) [2] 4.1.1.2. Chemotherapy: Single agent carboplatin: 1-2 doses at area under the curve 7 (EL-1) [3] 4.1.1.3. Radiotherapy: Infradiaphragmatic para-aortic strip only and in patient with prior scrotal surgery, ipsilateral iliac nodes should be included (EL-1). [4, 5] cisplatin (VeIP) regimen [11] (EL-2) or 4.1.6.2. Four cycles of paclitaxel, ifosfamide, and cisplatin (TIP) regimen (EL-2). [12] 4.1.7. Management of patients failing second-line chemotherapy: Patients will be treated with monotherapy or combination of paclitaxel and gemcitabine (for those who did not receive paclitaxel before), gemcitabine and oxaliplatin, or oral etoposide. [13] [16, 17] 4.2.1.1.2. T w o c y c l e s o f B E P re gimen (EL-1), [16] [17] [18] also one cycle of BEP chemotherapy can be considered in such cases [18] 4.2.1.1.3. Open nerve sparing RPLND to be done only in high volume tertiary care centers (EL-2), [18] further therapy will depend on the pathological result as follow: 4.2.1. [19] Fur ther therapy will depend on the pathological stage as in item 4.2.1. [20, 21] only if the nodal metastases is in the primary landing zone and in selected patients, it should be done only in high volume center by experienced uro-oncologist. [25] w i t h E P, V I P o r T I P (see below) (EL-2 with autologous stem-cell transplant. [26] 5. Salvage treatment for seminoma and nonseminoma 5.1. Conclusive recommendations cannot be made at present 5.2. Prognosis is variable with 2 years survival rate ranging between 75% and 6% based on prognostic score 5.3. Options includes TIP × 4 or VeIP × 4 or high-dose chemotherapy with TI-CE mainly for patients at second-line setting 5.4. Carboplatin based high-dose chemotherapy as third line or later is an option, despite absence of randomized trials in this area 5.5. Desperation surgery should be part of the strategy whenever possible, particularly in patients with localized disease and with poor response to chemotherapy. [27] Financial support and sponsorship
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